However, several critical questions remain to be addressed: (1) the precise molecular targets of AST in regulating ferroptosis and cGAS-STING signaling, (2) the in vivo efficacy and safety profile of AST in psoriatic models, and (3) the potential synergistic effects of AST with existing psoriasis therapies. Here, STING1 is linked to psoriasis.